Lysatpharma GmbH is a German biotechnology company founded in 2018 and based in Jena, Germany.

Lysatpharma focuses on regenerative medicine and new biomedical immunotherapies based on extracellular vesicles (exosomes). In collaboration with the University Hospital Jena (Germany), the company is developing novel immunotherapies for acute and chronic systemic inflammatory diseases. Lysatpharma has a patented technology for purifying exosomes from blood donations. The exosomes derived from platelets have immunomodulatory and regenerative properties. They are being developed as a therapy for inflammatory diseases.

For more information, please visit: www.lysatpharma.com